With 100% Alcon Ownership, Novartis Forms New Eye Care Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis reaches agreement to buy the part of Alcon it doesn't already own for $12.9 billion, ending months of squabbling with Alcon minority shareholders.
You may also be interested in...
Ophthalmology M&A Engine Keeps Roaring As Akorn Buys Out Hi-Tech
CEO Raj Rai calls the transaction a “transformative event” for Akorn that will be instantly accretive and produce between $15 million and $20 million of run-rate synergies within 12 months. Acquisition of Hi-Tech adds prescription and OTC products, 18 filed ANDAs and increased manufacturing capability.
Ophthalmology M&A Engine Keeps Roaring As Akorn Buys Out Hi-Tech
CEO Raj Rai calls the transaction a “transformative event” for Akorn that will be instantly accretive and produce between $15 million and $20 million of run-rate synergies within 12 months. Acquisition of Hi-Tech adds prescription and OTC products, 18 filed ANDAs and increased manufacturing capability.
Top Changes At Bayer And Novartis As Vasella Goes, Reinhardt Returns
It’s all change at two of Europe’s largest pharmaceutical concerns as leading light Daniel Vasella retires at Novartis and Bayer Healthcare’s chairman Jorg Reinhardt moves across to replace him as non-executive chairman.